News & Press Releases

Mintz announces that Member Kurt Steinkrauss has been ranked as a Band 2 attorney for Private Wealth Law in Massachusetts in the Chambers High Net Worth 2025 Guide.

Mintz advised on Gallion Health’s spinout from the University of Maryland Medical System (UMMS), marking the first company to emerge from the health system’s technology and incubation studio, iHarbor Innovation Center. The Center focuses on creating technology-based solutions to common problems facing health care institutions. Gallion Health is an award-winning cloud-based digital supply chain application that was launched at UMMS four years ago. 

Mintz announces that Associate Courtney Herndon has received the firm’s 2025 Richard Mintz Pro Bono Award. Presented annually by the firm’s Pro Bono Committee, the award honors one attorney whose exceptional commitment to pro bono service reflects Mintz’s dedication to advancing access to justice.

Ruth Jin has joined Mintz as a Member in the firm’s Corporate Practice with a focus on investment fund formation, liquidity strategies, governance, investment transactions, and securities offerings.

Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share.  The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.

Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.